• Alexandra Poinas, Pierre Perrot, Judith Lorant, Olivier Nerrière, Jean-Michel Nguyen, Soraya Saiagh, Cécile Frenard, Audrey Leduc, Olivier Malard, Florent Espitalier, Franck Duteille, Anne Chiffoleau, Florence Vrignaud, Amir Khammari, and Brigitte Dréno.
• Clinical Investigation Centre CIC1413, Nantes INSERM and CHU Nantes, 5, allée de l'île Gloriette, 44093, Nantes Cedex 1, France. alexandra.poinas@chu-nantes.fr.
• Trials. 2019 Oct 28; 20 (1): 612.

BackgroundWound repair is one of the most complex biological processes of human life. Allogeneic cell-based engineered skin substitutes provide off-the-shelf temporary wound coverage and act as biologically active dressings, releasing growth factors, cytokines and extracellular matrix components essential for proper wound healing. However, they are susceptible to immune rejection and this is their major weakness. Thanks to their low immunogenicity and high effectiveness in regeneration, fetal skin cells represent an attractive alternative to the commonly used autologous and allogeneic skin grafts.Methods/DesignWe developed a new dressing comprising a collagen matrix seeded with a specific ratio of active fetal fibroblasts and keratinocytes. These produce a variety of healing growth factors and cytokines which will increase the speed of wound healing and induce an immunotolerant state, with a slight inflammatory reaction and a reduction in pain. The objective of this study is to demonstrate that the use of this biological dressing for wound healing at the split-thickness skin graft (STSG) donor site, reduces the time to healing, decreases other co-morbidities, such as pain, and improves the appearance of the scar. This investigation will be conducted as part of a randomized study comparing our new biological dressing with a conventional treatment in a single patient, thus avoiding the factors that may influence the healing of a graft donor site.DiscussionThis clinical trial should enable the development of a new strategy for STSG donor-wound healing based on a regenerative dressing. The pain experienced in the first few days of STSG healing is well known due to the exposure of sensory nerve endings. Reducing this pain will also reduce analgesic drug intake and the duration of sick leave. Our biological dressing will meet the essential need of surgeons to "re-crop" from existing donor sites, e.g., for thermal-burn patients. By accelerating healing, improving the appearance of the scar and reducing pain, we hope to improve the conditions of treatment for skin grafts.Trial RegistrationClinicalTrials.gov, ID: NCT03334656 . Registered on 7 November 2017.

13 keywords...

hide…